Peter le, MD
Gastroenterology · Castle Rock, CONPI 1942460209
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $113,184 of the $138,055 with a category attached, or 82.0%. 32 manufacturers reported payments, led by Phathom Pharmaceuticals, Inc. at 39.2% of the total. 2025 is the largest year on record at $67,927, more than ten times the $5,472 reported in 2019. Among gastroenterology clinicians in CO with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 660 payments — averaging $209.17 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Phathom Pharmaceuticals, Inc.$54K
- Takeda Pharmaceuticals U.S.A., Inc.$35K
- AbbVie$32K
- Ardelyx, Inc.$9K
- Ironwood Pharmaceuticals, Inc$2K
- Johnson & Johnson$767
- plus $5K from 26 others
What the payments were for
- Speaking & faculty fees$113,18482%
- Travel & lodging$10,9928%
- Food & beverage$13,82410%
- Education$560%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Phathom Pharmaceuticals, Inc. | 78 | $54,182 |
| Takeda Pharmaceuticals U.S.A., Inc. | 101 | $34,831 |
| AbbVie(2 entities) | 172 | $32,313 |
| Ardelyx, Inc. | 25 | $8,975 |
| Ironwood Pharmaceuticals, Inc | 7 | $2,453 |
| Johnson & Johnson(3 entities) | 36 | $767 |
| Bristol Myers Squibb | 46 | $732 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 39 | $729 |
| Pfizer | 39 | $589 |
| Lilly USA, LLC | 15 | $401 |
| Sanofi | 18 | $347 |
| Regeneron Healthcare Solutions, Inc. | 12 | $291 |
| Gilead | 14 | $288 |
| QOL Medical, LLC | 10 | $216 |
| Intercept Pharmaceuticals, Inc. | 7 | $117 |
| Organon | 6 | $100 |
| Ipsen Biopharmaceuticals, Inc | 4 | $94 |
| Ferring Pharmaceuticals Inc. | 4 | $78 |
| Merck | 4 | $72 |
| Nestle Healthcare Nutrition Inc. | 4 | $66 |
| Redhill Biopharma Inc. | 4 | $59 |
| UCB, Inc. | 2 | $53 |
| Madrigal Pharmaceuticals | 2 | $52 |
| Micro-tech Endoscopy USA, Inc. | 1 | $51 |
| Laborie Medical Technologies Corp. | 1 | $42 |
| Shire North American Group Inc | 2 | $39 |
| Daiichi Sankyo Inc. | 2 | $30 |
| Amgen | 1 | $22 |
| Braintree Laboratories, Inc. | 1 | $20 |
| Alfasigma USA, Inc. | 1 | $18 |
| Albireo Pharma, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$138,055 in reported general payments places this provider in the 95th percentile of 304 gastroenterology providers in Colorado.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 13 | $102,952 |
| RinvoqUpadacitinib | 12 | $73,335 |
| ViberziEluxadoline | 22 | $36,212 |
| LinzessLinaclotide | 32 | $29,046 |
| SutabSod Sulf/Pot Chloride/Mag Sulf | 63 | $10,293 |
| Diphenhydramine Hcl | 47 | $3,721 |
| Colestipol Hcl | 30 | $3,555 |
| Omeprazole | 148 | $2,594 |
| Balsalazide Disodium | 12 | $1,706 |
| Pantoprazole Sodium | 110 | $1,018 |
| Mercaptopurine | 14 | $901 |
| Sodium Chloride0.9 % Sodium Chloride | 27 | $901 |
| Diphenoxylate-AtropineDiphenoxylate Hcl/Atropine | 27 | $754 |
| Famotidine | 57 | $682 |
| Ondansetron OdtOndansetron | 17 | $556 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRinvoq, Viberzi, Linzess | $32,313 | $138,59366 claims |
| Braintree Laboratories, Inc.Sutab | $20 | $10,29363 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 304 gastroenterology providers in Colorado.
Other gastroenterology in Castle Rock
- Christopher HaydekCastle Rock$112K
- Lisa MathewCastle Rock$10K
- Peter McNallyFt Carson$1.1M
- Douglas AdlerColorado Springs$910K
- Marcelo KugelmasEnglewood$660K
- Mary Ann HuangDenver$408K
- Gareth WeinerThornton$382K
- Matthew NicholsLone Tree$360K
- Nathan SchomakerLone Tree$344K
- Joshua SteinbergNorthglenn$266K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.